Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CALML3 | P27482 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14168202 | 0.87 | — | — | |
| SCHEMBL10151432 | 0.87 | — | — | |
| SCHEMBL10131303 | 0.87 | — | — | |
| SCHEMBL15757516 | 0.80 | MAPK1 (0.46) | MAOAMAOBMAPK1L3MBTL1CALML3 | |
| SCHEMBL9226555 | 0.80 | MAPK1 (0.46) | MAOAMAOBMAPK1L3MBTL1CALML3 | |
| SCHEMBL9228870 | 0.80 | MAPK1 (0.46) | MAOAMAOBMAPK1L3MBTL1CALML3 | |
| SCHEMBL10249590 | 0.80 | BRD4 (0.46) | MAOAMAOBBRD4IRAK4GRM2 | |
| SCHEMBL27296384 | 0.80 | MAOA (0.41) | MAOAMAOBMAPK1L3MBTL1CALML3 | |
| SCHEMBL9492421 | 0.78 | L3MBTL1 (0.57) | MAOAMAOBMAPK1L3MBTL1GRM2 | |
| SCHEMBL14168549 | 0.77 | MAOA (0.39) | MAOAMAOBMAPK1L3MBTL1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | MAOA 619/4885MAOB 89/4885MAPK1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.